The Hidden Employment Crisis Facing Cancer Patients
A Social Commentary By: Lennard M. Goetze, Ed.D / Barbara Bartlik, MD
Disclaimer: This commentary does not suggest that employers openly terminate workers because they have cancer. In most cases, employment actions are tied to broader issues such as prolonged absences, repeated medical leave, reduced availability, performance disruption, staffing pressures, or disputes over accommodations during treatment. However, as reports and legal complaints continue to surface, serious illness—particularly cancer requiring extensive time away from work—can place employees in a vulnerable position where their job security may be jeopardized. This social commentary examines that growing concern: the intersection of health hardship, workplace pressures, and the need for fairer protections for individuals managing life-threatening disease while trying to remain employed.
Cancer
changes everything in a moment. It alters health, finances, family dynamics,
and emotional stability. Yet for many patients, another crisis quietly emerges
after diagnosis: the fear of losing their job. While public conversations often
focus on treatment and survival, far less attention is given to employment
vulnerability—the growing pattern of workers being sidelined, pressured out, or
terminated after serious illness.
Advocates
describe it as one of the most overlooked burdens of cancer care. Four-time
cancer survivor and patient advocate SCOTT BAKER has seen it firsthand. Through
years of supporting patients and families, he says many workers discover that
the moment they need compassion most is when job security becomes uncertain.
“There
are certain businesses where it’s just too much time off,” Baker explained.
“They need you to be a ten out of ten every day, so they say, we can’t keep
you.” This is not simply an HR issue. It
is a public health concern, an economic concern, and increasingly, a legislative
concern.
The
Unspoken Pattern of Employment Risk
Many workers assume that once
diagnosed with cancer, legal systems automatically shield them from
termination. The reality is more complicated. Some protections exist under
disability and leave laws, but they are often narrow, time-limited, or
dependent on company size, job tenure, and documentation requirements. That
leaves countless employees exposed.
Baker
recalled cases involving young nurses who had been employed for less than a
year when they were diagnosed. Because they had not yet qualified for leave
protections, they were let go. “They didn’t qualify for FMLA, so they just let
them go,” he said.
Healthcare
workers themselves are not immune. In fact, Baker emphasized that hospitals and
medical institutions can reflect the same pressures seen in other
industries—staffing shortages, productivity demands, and limited tolerance for
extended absence. For patients, the message can feel brutal: get well quickly,
or become replaceable.
Even
After Treatment, the Battle Continues
One of the least understood
realities of cancer recovery is that treatment completion does not equal full
recovery. Many survivors return to work carrying fatigue, neuropathy, cognitive
fog, anxiety, chronic pain, or emotional trauma. “They come back, and they’re
not the same,” Baker noted. “It takes a long time to recover.”
This
creates a dangerous gap. Employers may expect immediate peak performance, while
survivors are still rebuilding physically and mentally. In fast-paced or
high-output environments, workers may be quietly managed out, demoted, or
judged against pre-illness standards. The result is a second trauma layered on
top of the first.
The
Self-Employed Face a Different Crisis
For entrepreneurs, freelancers, and
small business owners, illness can be even more devastating. There may be no
paid leave, no corporate benefits, and no substitute income stream. “They go
from breadwinner to no bread,” Baker said bluntly. This group often falls through policy cracks.
They are workers without the protections many traditional employees assume
exist.
What
Can Be Done Legislatively?
Advocates increasingly argue that
cancer survivorship must include employment security. Several reforms could
make a meaningful difference:
1. Expand Medical Leave Eligibility: Current leave laws often exclude newer employees, part-time
workers, or workers in smaller companies. Reform should shorten waiting periods
and broaden eligibility for serious illness.
2. Modernize Temporary Disability Benefits: Baker recently advocated for reform of temporary disability
insurance, noting that some benefit levels remain shockingly outdated. “$189 a
week is not cutting it,” he said. For many families, that amount would not
cover transportation to treatment, let alone rent or groceries.
3. Protect Return-to-Work Rights: Legislation could require reasonable phased returns,
flexible scheduling, and medical accommodation for cancer survivors re-entering
the workforce.
4. Strengthen Anti-Retaliation Enforcement: Some workers are not formally fired—they are squeezed out
through reduced hours, negative reviews, or hostility after disclosure. Better
enforcement mechanisms are urgently needed.
5. Incentivize Retention: Tax
credits or subsidies for employers who retain and accommodate workers
undergoing treatment could turn compassion into practical policy.
Work-Arounds
for Workers Right Now
Until laws catch up, patients need strategies:
·Disclose medical issues carefully
and document all communications.
·Request accommodations in writing.
·Understand leave rights under
federal and state law.
·Consult employment attorneys or
patient advocacy groups early.
·Build relationships with supervisors
who may advocate internally.
Baker
credits a supportive supervisor with helping save his own position during
prolonged treatment. Without that ally, the outcome may have been very
different. That should not depend on
luck.
A
Larger Moral Question
How a society treats workers during
illness reveals its values. Cancer patients are not disposable assets. They are
teachers, nurses, tradespeople, executives, parents, veterans, and community
members fighting for their lives. To punish illness with unemployment is not
efficiency—it is failure.
Conclusion
The hidden employment crisis facing
cancer patients deserves national attention. Behind many survival stories lies
another story of lost income, lost dignity, and preventable hardship. The goal
of modern medicine is not merely to keep people alive—it is to preserve their
ability to live.
Scott
Baker’s warning is clear: the risk is real, widespread, and often invisible.
The next frontier of survivorship is not only better treatment. It is better
protection. No one battling cancer should also have to battle for the right to
keep their job.
PART 2: CLINICAL PERSPECTIVE
WORK IS
MEDICINE: WHY A CANCER DIAGNOSIS SHOULD NOT END A PERSON’S CAREER
Written by Dr. Robert L.
Bard
I have spent my professional life studying disease through imaging,
diagnostics, and the realities of patient care. Over decades of working with
cancer patients, I have learned one truth that too many employers fail to
understand: a cancer diagnosis does not automatically mean disability,
incapacity, or the end of productivity.
That is why I stand in full support of the
concerns raised by Scott Baker in his
important discussion about workers being fired because of cancer. This issue is
real, it is harmful, and in many cases, it is based on fear rather than fact.
Too often, people are judged by a diagnosis instead of their actual condition,
their strength, or their ability to contribute. As physicians, employers, and
as a society, we must do better.
The Diagnosis Is Not the Disability
One
of the greatest misconceptions in the workplace is the belief that once a
person hears the word “cancer,” they are no longer able to function. This is
medically inaccurate. Many cancers today are treatable, manageable,
slow-growing, or responsive to therapy. Some remain stable for years or
decades.
I have personally followed patients with
low-grade prostate cancer who continue to live normal, active, productive
lives. With modern imaging, surveillance, and appropriate care, we can often
confirm that their condition has not progressed and does not impair their daily
function.
I have also known patients with metastatic
disease who still climb stairs, go to work, care for families, and remain
deeply engaged in life. Their diagnosis did not define their usefulness. Their
resilience did.
Work Can Be Healing
Employment
is not only about income. Work gives structure, purpose, identity, dignity, and
hope. For many patients, returning to work or continuing to work becomes part
of recovery. It restores normalcy during a frightening time. It reminds them
they are still needed.
I recall experiencing severe postoperative
pain years ago after a dental procedure. The discomfort was so intense that I
went back to work simply to focus my mind on something productive rather than
on suffering. That experience taught me that meaningful activity can help
redirect pain, anxiety, and despair. Cancer patients deserve that same opportunity.
The Role of Medical Verification
Today
we have advanced tools that can help objectively assess a patient’s status.
Through ultrasound imaging, Doppler flow studies, elastography, and other
noninvasive technologies, we can monitor tumor behavior, treatment response,
and physical function.
This means decisions about employment should
not be based on assumptions or stigma. They should be based on facts. If a
patient is medically capable of working, physicians should feel empowered to
document that reality. Employers should welcome that guidance rather than fear
it.
A Special Concern: Healthcare Workers
I was
especially troubled to hear reports of nurses and healthcare workers losing
jobs soon after a diagnosis. That is not only unjust—it is counterproductive.
When a nurse with cancer continues to serve
with strength and professionalism, it sends a powerful message to every patient
in that hospital: survival is possible, life continues, and illness does not
erase value. Those workers become living symbols of courage. To remove them
because “it doesn’t look good” is a failure of compassion and leadership.
Final Word
A
cancer diagnosis should trigger support, not suspicion. It should lead to
accommodation where needed, not automatic termination. We need stronger
workplace protections, physician-backed return-to-work pathways, and a national
understanding that many people with cancer can continue to live and work
successfully.
Cancer
is a health challenge. It should never become an employment sentence.
NEWS REFERENCES:
1. United Airlines Employee Claims He Was Fired Mid-Chemo Session: A United Airlines worker with stage 4 lymphoma alleged he was fired over the phone during chemotherapy for “taking too much time off work.” Read People Magazine Report
2. Independent Report on Same United Airlines Lawsuit: Detailed coverage of the federal complaint, including allegations he continued working while undergoing treatment. Read The Independent Report
3. Black Enterprise Coverage: Fired After Using PTO for Chemotherapy: Follow-up reporting focused on the use of accrued leave for cancer treatment and alleged termination. Read Black Enterprise Report
4. Nurse Alleges Firing While Fighting Breast Cancer: Public reporting described a nurse claiming termination after requesting leave connected to surgery and treatment. (Referenced in prior public reports.) Search Related Public Coverage
5. Workers Losing Jobs Before FMLA Eligibility: The United complaint alleges termination one week before the employee qualified for federal protected leave. Read FMLA Allegation Details
6. National Pattern: Cancer Patients Reporting Employment Retaliation- This case has drawn public attention because it reflects a broader pattern of workers claiming punishment after serious diagnoses. Read National Discussion Coverage
7. Lawsuit Includes ADA Disability Discrimination Claims: The complaint reportedly includes violations under the Equal Employment Opportunity Commission framework and disability law standards. Read Legal Allegations
8. “No One Should Have to Choose Between Health and Livelihood”: The employee’s attorney framed the case as forcing workers to choose between treatment and employment. Read Attorney Statement
Why Clinical Nutrition Is Essential for Cancer
Survivors and the Fight for Quality of Life
Written by: Barbara Bartlik, MD / Lennard M. Goetze, Ed.D
Like the hummingbird, one of
nature’s smallest yet most resilient creatures, cancer survivors often require
powerful nourishment delivered in small, efficient ways. The hummingbird
survives through frequent feeding, drawing concentrated energy from flowers
while its wings beat with extraordinary speed and precision. In much the same
way, survivors recovering from chemotherapy or radiation may need steady,
nutrient-dense meals throughout the day to restore strength, sustain
metabolism, and support healing. Its ability to hover, adapt direction
instantly, and keep moving despite immense energy demands mirrors the role of
clinical nutrition in rehabilitation: providing the fuel, balance, and
resilience needed to regain motion, vitality, and forward momentum after treatment.
Survival Is
Only the Beginning
Modern medicine has changed the
landscape of cancer care. More people are surviving diagnosis, enduring
chemotherapy, completing radiation, and living beyond what once seemed
impossible. But after treatment ends, many survivors discover a new challenge
begins: rebuilding the body, restoring energy, and reclaiming quality of life.
Cancer therapy may remove disease,
but it can also leave behind fatigue, weakness, digestive distress,
inflammation, immune suppression, hormonal imbalance, weight loss or unwanted
weight gain, and profound muscle depletion. Many survivors are told they are
“done,” yet their body says otherwise.
This is where nutrition becomes one
of the most powerful tools in rehabilitation.
At RehabScan,
recovery is viewed as more than the absence of cancer. It means strength,
function, resilience, vitality, and the ability to live fully again. Clinical
nutrition is central to that mission. Food is not merely calories—it is tissue
repair, immune support, metabolic recovery, hormonal balance, and long-term
defense against recurrence. For survivors, every meal can become part of the
healing process.
Why Nutrition Matters
After Chemotherapy and Radiation
Cancer treatments often place
enormous stress on the body. Chemotherapy may alter taste, reduce appetite,
damage gut lining, impair digestion, and contribute to muscle loss. Radiation
can inflame tissues, affect swallowing, appetite, bowel habits, or absorption
depending on the treatment site. Even targeted therapies and hormone treatments
may create metabolic strain, weight changes, or fatigue.
The National Cancer Institute notes
that malnutrition and loss of lean body mass can worsen outcomes, reduce
quality of life, and increase complications.That means post-treatment nutrition is not cosmetic—it is clinical. Proper nutrition can help
survivors:
Restore
lost muscle and strength
Improve
stamina and daily energy
Support
immune recovery
Reduce
chronic inflammation
Stabilize
blood sugar and metabolism
Promote
healthy body weight
Improve
digestion and gut health
Protect
cardiovascular health
Enhance
mood and cognitive clarity
Lower
risk factors linked to recurrence
The Nutrition Goals of
Survivorship
1. Rebuild Strength and
Lean Muscle
Many survivors lose muscle during
treatment, even if body weight remains stable. This loss of lean tissue can
drive weakness, falls, slower metabolism, and ongoing fatigue.
Protein is not about
bodybuilding—it is about preserving independence.
2. Support the Immune
System
The immune system may remain taxed
long after therapy. Nutrient-dense foods can help support normal immune
function.
Focus on:
Colorful
vegetables and fruits
Zinc-rich
foods (pumpkin seeds, seafood, beans)
Selenium
sources (Brazil nuts, seafood)
Vitamin
C foods (berries, citrus, peppers)
Vitamin
D monitoring with physician guidance
Omega-3
fats from salmon, sardines, flax, chia
3. Calm Inflammation
Persistent inflammation has been
associated with fatigue, pain, metabolic dysfunction, and chronic disease risk.
An anti-inflammatory nutrition pattern includes:
Olive
oil
Nuts
and seeds
Fatty
fish
Leafy
greens
Cruciferous
vegetables
Berries
Herbs
and spices such as turmeric and ginger
Reduced
ultra-processed foods and sugary beverages
4. Help Defend Against
Recurrence
No single food “cures” or
guarantees prevention. But strong evidence supports healthy dietary patterns
rich in plant foods, whole grains, healthy weight maintenance, and physical
activity as part of reducing cancer risk and improving survivorship outcomes.
The Best Eating Pattern
for Survivors
Most experts support a
Mediterranean-style, plant-forward approach.
That means:
Half
the plate vegetables and fruit
Whole
grains such as oats, quinoa, brown rice
Beans
and legumes often
Fish
and lean proteins regularly
Olive
oil as a primary fat
Nuts
and seeds daily in moderation
Limited
processed meats
Reduced
refined sugar
Moderate
portions
Smart
hydration
This style of eating supports the
heart, brain, metabolism, and inflammatory balance—all major concerns for
survivors.
Special Problems That Need
Clinical Nutrition
Some survivors need more than
general advice. They need individualized medical nutrition therapy.
Examples include:
Difficulty
swallowing after head/neck treatment
Chronic
diarrhea or bowel issues after pelvic radiation
Severe
weight loss
Sarcopenia
(muscle wasting)
Diabetes
after steroid use
Hormonal
weight gain
Taste
changes or appetite loss
Bone
loss risk
Kidney
concerns
Food
fears or restrictive eating after diagnosis
This is where referral to an
oncology dietitian or clinical nutrition professional becomes essential.
One-size-fits-all advice can fail
complex survivors.
Nutrition and Mental
Recovery
Food does far more than feed the body—it also helps regulate the brain. For many cancer survivors, the emotional and cognitive effects of treatment can linger long after chemotherapy, radiation, or surgery has ended. Patients often describe “chemo brain,” a frustrating condition marked by memory lapses, mental fog, slower processing speed, poor concentration, and difficulty multitasking. Others struggle with anxiety, depression, irritability, sleep disruption, and emotional fatigue after months of physical and psychological stress.
The brain is highly dependent on steady nutrition. When blood sugar fluctuates dramatically due to skipped meals, excessive sugar intake, or poor eating habits, mood and focus often suffer. This is why balanced meals containing protein, healthy fats, fiber, and complex carbohydrates can be so important during recovery. Stable blood sugar may help improve concentration, reduce irritability, and provide more consistent daily energy.
Certain nutrients are especially valuable for mental recovery. Omega-3 fatty acids, found in salmon, sardines, walnuts, flaxseed, and chia seeds, are associated with brain health, mood regulation, and reduced inflammation. Magnesium-rich foods such as leafy greens, pumpkin seeds, almonds, beans, and dark chocolate may support relaxation, sleep quality, and nervous system balance. B vitamins, found in eggs, legumes, whole grains, and lean proteins, are essential for cognitive function and energy metabolism.
Hydration is another overlooked factor. Even mild dehydration can worsen headaches, fatigue, and mental fog. Survivors should prioritize water intake throughout the day, especially if medications or lingering side effects affect fluid balance.
Reducing alcohol intake may also improve sleep quality, emotional stability, and liver recovery after treatment. Excess alcohol can impair cognition, worsen anxiety, and interfere with restorative sleep patterns.
Sometimes the most therapeutic meal is not expensive or exotic—it is simply consistent nourishment after months of chaos. A bowl of oatmeal, a vegetable omelet, grilled salmon with greens, or yogurt with berries can become part of rebuilding emotional resilience. In survivorship, nutrition is not only about strength and immunity—it is also about clarity, calm, and helping the mind heal alongside the body.
RehabScan’s Vision: Nutrition as Rehabilitation
At RehabScan,
survivorship should include comprehensive restoration:
Functional
imaging
Strength
recovery
Cardiovascular
support
Cognitive
rehabilitation
Hormonal
optimization
Mental
wellness
Clinical
nutrition
Nutrition should sit beside physical
therapy, mental health care, exercise oncology, and medical surveillance—not
outside the system. Because a survivor does not just need to be monitored. They
need to be rebuilt.
Practical First Steps for
Survivors
Start simply:
Add
protein to breakfast
Eat
vegetables twice daily minimum
Replace
sugary drinks with water or tea
Walk
daily if cleared medically
Build
meals around whole foods
Track
fatigue and digestion patterns
Ask
for oncology dietitian guidance
Strength
train when approved
Prioritize
sleep
Stay
consistent, not perfect
Conclusion: Recovery Can
Be Eaten One Day at a Time
Cancer treatment may save life. But
nutrition helps restore living. It helps the weak become stronger. It helps the
exhausted regain energy. It helps the fearful feel proactive again. It supports
the immune system, preserves muscle, steadies metabolism, and contributes to a
terrain less favorable to recurrence.
Survivors deserve more than
discharge papers and follow-up scans. They deserve a roadmap back to vitality. That roadmap should include food as
medicine, food as fuel, and food as rehabilitation.
At RehabScan,
the future of survivorship is clear: detect disease, treat disease, then
rebuild the human being. And rebuilding often begins at the
table.
Understanding What Breaks Down in Lymphedema By: Lennard M. Goetze, Ed.D
The lymphatic system is one of the body’s most underappreciated circulatory networks, yet it plays a critical role in maintaining fluid balance, immune defense, and tissue health. When this system fails, the result is lymphedema—a chronic, progressive condition defined by the accumulation of protein-rich fluid in the interstitial spaces. To understand lymphedema, one must first understand how the lymphatic system is designed to work—and what happens when its delicate mechanics are disrupted.
At its core, the lymphatic system functions as a drainage and filtration network. Blood capillaries constantly leak fluid, proteins, and cellular waste into surrounding tissues. Approximately 10% of this fluid is not reabsorbed by the venous system and must instead be collected by lymphatic capillaries. These microscopic vessels are uniquely structured with overlapping endothelial cells that act as one-way valves, allowing fluid to enter but not escape. Once inside, this fluid—now called lymph—is transported through progressively larger lymphatic vessels.
These vessels are not passive conduits. They possess intrinsic contractility, aided by surrounding skeletal muscle movement and pressure gradients created by breathing and arterial pulsation. Along the way, lymph passes through lymph nodes—small, bean-shaped structures that serve as immunological checkpoints. Here, pathogens, cellular debris, and abnormal cells are identified and neutralized. The filtered lymph is eventually returned to the bloodstream via the thoracic duct or right lymphatic duct, completing the cycle.
Lymphedema occurs when this transport system is compromised. The failure can be mechanical, structural, or functional. In many cancer patients, the most common cause is lymph node removal or damage during surgery or radiation therapy. When nodes are excised or scarred, the downstream pathways become obstructed. Fluid that would normally be cleared begins to accumulate in the tissues.
However, the problem extends beyond simple fluid backup. The lymphatic system is responsible for clearing proteins from the interstitial space. When these proteins remain, they increase osmotic pressure, drawing even more fluid into the area. This creates a self-perpetuating cycle of swelling. Over time, the stagnant, protein-rich environment triggers chronic inflammation. Fibroblasts become activated, leading to tissue fibrosis, skin thickening, and a loss of elasticity. What begins as soft, reversible swelling can evolve into a firm, irreversible condition.
Additionally, lymphatic vessels themselves can lose function. Damage to their muscular walls or valves impairs their ability to contract and propel lymph forward. This condition, sometimes referred to as lymphatic insufficiency, further reduces clearance capacity. The system becomes overwhelmed—not just blocked, but functionally exhausted.
The immune consequences are equally significant. With impaired lymph flow, immune surveillance is diminished. This leaves affected tissues more vulnerable to infections such as cellulitis, which can further damage lymphatic structures and accelerate disease progression.
In essence, lymphedema is not merely a condition of swelling—it is a failure of an entire physiological system. It reflects a breakdown in fluid dynamics, immune regulation, and tissue homeostasis. Understanding this complexity is essential. It shifts the conversation from cosmetic concern to systemic dysfunction, reinforcing the need for early detection, ongoing monitoring, and integrative management strategies aimed at restoring—not just compensating for—lymphatic flow.
PART 2:
Lymph Node Removal Is Not the End: Preventing
Lymphedema and Rebuilding Strength After Breast Cancer
Lymphatic drainage is one of the most essential—and often overlooked—processes in the body’s ability to heal, detoxify, and defend itself. The lymphatic system functions as a vast internal filtration network, quietly moving fluid through vessels and nodes to remove waste, toxins, and cellular debris while supporting immune surveillance. It plays a critical role in maintaining fluid balance and protecting against infection. Yet unlike the circulatory system, which is powered by the heart, the lymphatic system relies on movement—muscle contraction, breathing, and external stimulation—to keep fluid flowing. When this system is disrupted, such as after lymph node removal in breast cancer treatment, fluid can stagnate, leading to swelling, inflammation, and increased risk of complications like lymphedema.
This is where Manual Lymphatic Drainage (MLD) becomes a powerful therapeutic tool. MLD is a specialized, gentle technique that uses light, rhythmic, and highly targeted hand movements to stimulate lymph flow and redirect fluid around compromised areas. Unlike traditional massage, it is not designed to work deep into muscle tissue, but rather to activate the superficial lymphatic vessels just beneath the skin. By guiding fluid toward functioning lymph nodes, MLD helps restore circulation within the lymphatic system, reduce swelling, and support the body’s natural healing processes. For patients recovering from lymph node removal—particularly in breast cancer care—MLD is not just supportive therapy; it is a critical component of proactive rehabilitation and long-term lymphatic health.
Why Is Lymphatic Drainage
Important in Breast Cancer?
After lymph node removal (common in
breast cancer surgery), the body’s natural drainage pathways are disrupted. This can lead to:Fluid buildup,Swelling (lymphedema) and Inflammation & discomfort
Preventing
Lymphedema and Rebuilding Strength After Breast Cancer
Cancer rehabilitation is the structured, multidisciplinary effort to restore function, reduce treatment-related side effects, and help patients return to a meaningful quality of life after cancer therapy. Within this framework, managing lymphedema is not a side issue—it is a central pillar of recovery.
Lymphedema directly impacts mobility, strength, comfort, and daily function. Left unmanaged, it can lead to chronic swelling, tissue fibrosis, pain, and increased risk of infection. These are not isolated symptoms—they affect how a person moves, works, exercises, and even how they see themselves. For this reason, lymphedema care naturally belongs within cancer rehabilitation, where the goal is not just survival, but restoration.
A comprehensive cancer rehab model addresses multiple domains:
Physical Function: Restoring range of motion, strength, and endurance through guided exercise and movement therapy
Lymphatic Health: Managing fluid balance through manual lymphatic drainage, compression therapy, and monitoring
Pain and Tissue Health: Reducing inflammation, scar restriction, and discomfort
Neuromuscular Recovery: Rebuilding coordination and correcting compensatory movement patterns
Psychosocial Support: Addressing identity, confidence, and the emotional toll of physical change
Lifestyle Reintegration: Supporting return to work, activity, and independence
For men with breast cancer—who are often underrepresented in survivorship programs—this integrated approach is especially critical.
Ultimately, cancer rehabilitation reframes the journey: from simply removing disease to actively rebuilding the body. Managing lymphedema is not just about controlling swelling—it is about restoring movement, confidence, and long-term quality of life.
Lymphatic drainage
refers to the movement of lymph fluid through the body’s lymphatic system—a
network of vessels and nodes that helps remove waste, toxins, excess fluid, and
supports immune function.
What
Does the Lymphatic System Do?
Think
of the lymphatic system as the body’s cleanup
and filtration network. It:
Drains excess fluid from tissues
Filters harmful substances through lymph nodes
Transports immune cells to fight infection
Helps maintain fluid balance
Unlike the circulatory system, the
lymphatic system does not have a pump like
the heart. Instead, it relies on:
Muscle movement
Breathing
Manual stimulation (like massage)
What Is Manual Lymphatic Drainage
(MLD)?
Manual Lymphatic Drainage (MLD) is a
specialized, gentle massage technique designed to stimulate and redirect lymph flow. It involves:
The
goal is to help fluid move around blocked
or damaged areas, especially after lymph node removal.
Why Is Lymphatic Drainage
Important in Breast Cancer?
After
lymph node removal (common in breast cancer surgery), the body’s natural
drainage pathways are disrupted.
This can lead to:
Fluid buildup
Swelling (lymphedema)
Inflammation and discomfort
MLD helps:
Reduce swelling
Improve circulation
Prevent progression of lymphedema
Support healing and tissue health
Who Needs It?
Lymphatic
drainage is especially important for:
Breast cancer patients (men and women) after
lymph node removal
Patients with early or established
lymphedema
Individuals with swelling after surgery,
radiation, or injury
Key Takeaway
Lymphatic
drainage is not just a therapy—it’s a critical
component of recovery and long-term health after cancer treatment. It
supports what surgery disrupts. And when used early and consistently, it can be
the difference between temporary swelling
and a lifelong condition.
Beyond Survival A Cardiologist’s Perspective with Dr. Hwaida Hannoush
By: Lennard Goetze, Ed.D | Daniel Root | Regina Bessler, PhD
In an era when medicine is becoming increasingly specialized, few physicians
are as committed to bridging disciplines as Dr. Hwaida Hannoush, a cardiologist and functional
medicine practitioner whose work reflects the growing need for more
personalized, predictive, and preventive care. As the founder of Precimed Clinic, Dr. Hannoush
has built her clinical philosophy around one central belief: that precision medicine must be at the heart of
modern healthcare.
With a strong focus on women’s
heart health, preventive cardiology, and individualized
treatment strategies, Dr. Hannoush combines the rigor of traditional
cardiovascular medicine with the systems-based insight of functional medicine.
Her approach is rooted in uncovering the deeper drivers of disease rather than
simply managing symptoms. At Precimed Clinic, that means using advanced
diagnostics, nuanced interpretation, and personalized care plans to help
patients understand the “why” behind their cardiovascular risk—and, where possible,
reverse it.
But in a recent discussion about cancer rehabilitation and survivorship, Dr.
Hannoush turned her attention to a topic that remains dangerously
under-recognized in mainstream medicine: the cardiovascular consequences of cancer therapy. Her
message was clear, urgent, and clinically significant: for many cancer survivors, the battle does
not end when the tumor is gone.
The Overlooked Crisis in
Cancer Survivorship
Much of the public conversation around cancer treatment centers on
remission, recurrence, and tumor response. But according to Dr. Hannoush, there
is another threat quietly affecting survivors long after treatment has ended: cardiovascular injury. “I want to highlight,” she said, “that for
many cancer survivors, cardiovascular side effects of chemotherapy become a
serious — and often unrecognized — long-term threat.” That observation reframes
the survivorship conversation in an important way.
While cancer therapies are often life-saving, many of them can place
profound stress on the cardiovascular system. These effects may not always be
immediately visible, but over time they can contribute to heart failure, arrhythmias, coronary disease,
vascular dysfunction, metabolic injury, and long-term decline in physical
resilience. Research
shows that as cancer treatments become more effective and survival extends,
cardiovascular disease increasingly emerges as a dominant competing risk —
underscoring why protecting the heart during and after cancer treatment is not
optional, but essential.
This is the domain of cardio-oncology,
an evolving field focused on protecting heart health before, during, and after
cancer treatment. Dr. Hannoush has seen its importance firsthand, particularly
through her previous work evaluating heart function in patients undergoing
aggressive therapies.
She explained that this is not a fringe concern or a rare side effect. In
many cases, cardiovascular
complications become the dominant long-term health threat in cancer survivors,
particularly when these patients are not proactively monitored.What
sets Dr. Hannoush apart from many cardiologists is that she brings a second,
complementary lens to this work: functional medicine. While cardio-oncology
guidelines focus on monitoring heart function, managing cardiovascular risk
factors, and intervening when damage is detected, functional medicine asks a
deeper upstream question — why is this particular patient’s body uniquely
vulnerable, and what can be done to strengthen its resilience before and after
treatment begins? It is the integration of both frameworks that defines her
approach to survivorship care.
Why the Heart Is So
Vulnerable
One of the strengths of Dr.
Hannoush’s perspective is her ability to explain cardiac injury not as a single
event, but as a multi-layered biological
process.
According to her, chemotherapy and related treatments can harm the
cardiovascular system through several overlapping mechanisms. First, some drugs
can cause direct injury to the
myocardium, the muscular tissue of the heart itself. Others
disrupt the mitochondria,
the energy-producing structures that are especially abundant in cardiac tissue.
“The heart is rich in mitochondria,” she explained, “which is the power
source.”
When mitochondrial function is impaired, the heart may continue beating, but
it does so with reduced cellular efficiency and diminished reserve.Research
confirms that drugs like doxorubicin cause mitochondrial oxidative stress,
impaired energy production, and accelerated cell death in cardiac tissue — and
that a patient’s individual mitochondrial biology can influence how vulnerable
their heart is to this damage, pointing toward a future of more personalized
cardiac risk assessment.
Cancer treatments can also affect the coronary arteries, promoting atherosclerosis and
increasing the risk of infarction or heart attack. At the same time, they may
alter glucose regulation,
insulin sensitivity, lipid metabolism, oxidative stress, and inflammatory
burden—all of which increase cardiovascular risk even further.
Dr. Hannoush also emphasized the role of hormonal disruption, especially in therapies that
suppress sex hormones. In both women and men, these hormonal shifts can have
significant effects on vascular function, metabolism, and heart health. And perhaps
most compellingly, she pointed to a mechanism often left out of conventional
oncology conversations: the gut-heart
axis.
“Gut dysbiosis is a very important side effect of chemotherapy,” she said.
Because gut health influences inflammation, immune regulation, neurotransmitter
production, and metabolic stability, its disruption can have ripple effects far
beyond digestion. Emerging preclinical
evidence supports this concern: chemotherapy-induced gut dysbiosis can increase
intestinal permeability, allowing bacterial products to enter the bloodstream
and drive systemic inflammation that worsens cardiovascular injury — a pathway
now being studied as part of the gut-microbiota-heart axis. While direct proof
in humans is still developing, the mechanistic evidence is compelling and
growing.
One cardiovascular risk that
deserves particular mention — especially for readers who have undergone
treatment for breast cancer, Hodgkin lymphoma, or lung cancer — is radiation
therapy. When radiation involves the chest, it can damage the coronary
arteries, heart valves, and the pericardial sac through a process of chronic
inflammation and scarring. What makes this especially difficult to detect is
that these effects can remain silent for years or even decades after treatment
ends. Long-term survivors who received chest radiation as recently as their
twenties or thirties may not see cardiovascular consequences until midlife —
making awareness and surveillance in this population critically important.
Taken together, these mechanisms reveal a difficult truth: many cancer treatments affect not only the
tumor, but the body’s foundational systems of resilience.
The Problem with Waiting
Too Long
A major concern for Dr. Hannoush is
that conventional monitoring often catches cardiovascular damage too late. Traditionally,
clinicians look for a decline in ejection fraction (EF) ― a measure of how much blood the
heart pumps out with each beat. But by the time EF drops, injury may already be
well underway.
That is why she strongly advocates strain imaging, a more sensitive technique that evaluates
subtle deformation in the heart muscle before overt dysfunction appears. “You
don’t want to wait till the heart function drops,” she explained. “You want to
detect it earlier.”
This technology, commonly referred to as longitudinal strain, has become a valuable tool in
cardio-oncology because it can reveal subclinical deterioration in the myocardium before
symptoms emerge and before standard imaging appears abnormal.
For Dr. Hannoush, this represents one of the clearest examples of what
precision medicine should look like in practice: not reactive care, but early detection, functional monitoring, and
intervention before collapse. She also emphasized that such
monitoring should not be sporadic or incidental. Oncology patients, she argued,
should have structured
cardiovascular protocols that include echocardiograms,
biomarker tracking, and ongoing surveillance tailored to their treatment
exposure.
Cancer Rehab Must Be More
Than Physical Therapy
Another central theme in Dr.
Hannoush’s discussion was the need to redefine what “rehabilitation” actually
means after cancer treatment. From her perspective, true recovery is not limited to mobility or strength
training. It must include the broader restoration of the systems that treatment
may have disrupted—the heart,
skeletal muscle, metabolism, hormones, nutrition, detoxification pathways, and
even the microbiome.
She specifically highlighted skeletal
muscle as a major but often neglected player in survivorship.
“Muscles are very important,” she said, noting that skeletal muscle functions
as a kind of metabolic organ.
It helps regulate insulin sensitivity, glucose uptake, and systemic energy
balance. When cancer treatment contributes to muscle loss or frailty, the
patient does not just become weaker—they become metabolically more vulnerable.What is perhaps most striking is that this
vulnerability extends directly to the heart itself. Research shows that
chemotherapy-induced muscle wasting can involve the myocardium — a phenomenon
known as cardiac wasting — which thins the ventricular wall, raises cardiac
stress, and can contribute to arrhythmias and heart failure independently of
the direct toxic effects of the drugs. Protecting skeletal muscle and
protecting the heart, it turns out, are not separate goals.
That is one reason why she sees rehabilitation as something far broader than
conventional exercise recovery. It must also include metabolic rebuilding, nutrient replenishment,
and resilience restoration.
One Size Does Not Fit All
Perhaps the most defining principle
in Dr. Hannoush’s philosophy is her insistence that no two patients should be treated as
biologically identical. “One size does not fit all,” she said
plainly. That statement applies not only to cancer treatment, but to what comes
after it.
This is where Dr. Hannoush’s
functional medicine training becomes most distinct. Standard cardio-oncology
guidelines — supported by major cardiac societies — focus on monitoring
ejection fraction and strain, managing blood pressure and cholesterol, and
initiating medications when cardiovascular risk is identified. These are
essential and evidence-based. But functional medicine, as practiced by Dr.
Hannoush, asks what lies beneath those numbers: What is this patient’s
individual metabolic reserve? How are they processing and eliminating the
chemical burden of treatment? What nutritional or hormonal imbalances are
amplifying their vulnerability? These questions, she believes, are just as
important as the clinical measurements and often go unasked.
In her view, survivorship care should be personalized using tools such as:
Nutrigenomics
Pharmacogenomics
Metabolomics
Advanced nutrient and
functional testing
Individualized detoxification
assessment
Cardiovascular and metabolic
monitoring
This is especially important because two patients can receive the same
therapy and emerge with dramatically different outcomes depending on their
baseline reserves, detoxification capacity, nutrient status, hormonal balance,
and metabolic health. “It’s not only about the outside toxins,” she noted.
“Chemotherapy is one of the toxins, of course. And you need to know how your
body is able to detoxify.”
That perspective — grounded in
functional medicine’s core principle of identifying root causes rather than
managing symptoms — broadens the survivorship conversation in an important way.
Rather than viewing side effects as unavoidable collateral damage, Dr. Hannoush
challenges clinicians to ask a more useful question: what can be measured, supported, and
personalized before the damage becomes permanent?
An Awareness Gap That Must
Be Closed
Dr. Hannoush also noted that the field still
carries significant blind spots — and that women are among those most affected
by them. Sex and racial differences in how cancer therapies damage the heart
remain poorly understood, and most foundational cardio-oncology research has
not been designed with these differences in mind. Women who have undergone
treatment for breast cancer — many of whom received anthracycline-based
chemotherapy, HER-2 inhibitors, aromatase inhibitors, or chest radiation
represent a large and growing population of survivors with elevated
cardiovascular risk. Yet the evidence base to guide their care remains incomplete. For readers of this publication,
that gap is not abstract: it is personal. Advocating for thorough
cardiovascular surveillance after cancer treatment is not overcaution: it is
self-knowledge
Despite the growing evidence in
support of cardio-oncology and personalized survivorship care, Dr. Hannoush
believes one of the greatest barriers is still lack of awareness. Many patients are never fully informed
about what to watch for after treatment. Some assume that once chemotherapy is
complete, the danger has passed. Others may not connect symptoms like fatigue,
exercise intolerance, palpitations, weight gain, or metabolic instability to
prior treatment exposure.
That silence, she suggests, is part of the problem. For now, she believes
the most realistic first step is not perfection—it is education. “Raising awareness
will be good as a start,” she said.
That awareness must extend to patients, caregivers, oncologists,
cardiologists, and the broader rehab community. Because if survivorship is
truly the goal, then medicine must stop measuring success only by tumor
shrinkage and begin asking a more complete question:
What did the treatment
save—and what did it cost? In that conversation, Dr. Hwaida
Hannoush offers a voice that is both scientifically grounded and clinically
humane. Her work reminds the medical world that surviving cancer should not
mean silently inheriting a second chronic disease. If precision medicine is truly the future, then survivorship care must
become just as precise.
Dr. Hwaida Hannoush is a board-certified cardiologist recognized for her work in women’s cardiovascular health, metabolic medicine, and healthy aging. She blends evidence-based cardiology with preventive and functional strategies to help patients protect heart health while improving long-term vitality. Her clinical focus explores how inflammation, insulin resistance, hormonal changes, stress, and lifestyle patterns influence cardiovascular risk—particularly in women and adults navigating midlife transitions. Known as both a physician and educator, Dr. Hannoush promotes early detection, personalized care, and multidisciplinary collaboration that integrates nutrition, endocrinology, and wellness principles to support stronger hearts and longer, healthier lives.
" As a functional medicine practitioner and metabolic cardiologist, I
strongly believe that the future of oncology must extend beyond tumor
eradication. Cancer care, in its highest form, is not complete without a
structured, personalized recovery phase that addresses
the biological terrain altered by both the disease and its treatment.
What we often see in clinical practice is that patients exit
conventional care having “completed” treatment, yet remain
physiologically depleted—mitochondrial dysfunction, persistent
inflammation, metabolic inflexibility, endothelial damage, and profound
shifts
in the neuroendocrine and immune systems. These are not secondary
concerns; they are central determinants of long-term outcomes,
recurrence risk, and quality of life. Rehabilitation, therefore, must be reframed as a precision-based
continuum of care. This includes restoring mitochondrial function,
correcting micronutrient deficiencies, rebalancing metabolic pathways,
supporting vascular health, and addressing the psychological
and emotional resilience required for true recovery. When we integrate
these elements, we move from survival to regeneration.
I would also encourage continued emphasis on measurable, objective
biomarkers within rehabilitation programs—markers of inflammation,
oxidative stress, metabolic health, and vascular function—so that
recovery is not only supported, but tracked and optimized
with the same rigor as active treatment."
References
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M., Bergler-Klein, J., ... & ESC Scientific Document Group. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. European Heart Journal, 43(41), 4229–4361. https://doi.org/10.1093/eurheartj/ehac244
Camilli, M., Del Buono, M. G., Sanna, T., & Abbate, A. (2024). Anthracycline cardiotoxicity in adult cancer patients: JACC state-of-the-art review. JACC: CardioOncology, 6(5), 643–660. https://doi.org/10.1016/j.jaccao.2024.07.016
Koutsoukis, A., Ntalianis, A., Repasos, E., Kastritis, E., Dimopoulos, M. A., & Paraskevaidis, I. (2018). Cardio-oncology: A focus on cardiotoxicity. European Cardiology Review, 13(1), 64–69. https://doi.org/10.15420/ecr.2018:4:2
Dobson, R., Ghosh, A. K., Ky, B., Marwick, T., Stout, M., Harkness, A., & Senior, R. (2021). British Society of Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. JACC: CardioOncology, 3(1), 1–16. https://doi.org/10.1016/j.jaccao.2021.01.011
Belger, C., Friedmann Angeli, J. P., & Bruns, D. R. (2024). Doxorubicin-induced cardiotoxicity and risk factors. Biomedicine & Pharmacotherapy, 170, 115980. https://doi.org/10.1016/j.biopha.2023.115980
Qiu, Y., Gao, J., Chen, Y., & Wang, J. (2023). Anthracycline-induced cardiotoxicity: Mechanisms, monitoring, and prevention. Frontiers in Cardiovascular Medicine, 10, 1242596. https://doi.org/10.3389/fcvm.2023.1242596
Gent, D. G., Dent, S., & Lyon, A. R. (2023). The 2022 European Society of Cardiology cardio-oncology guidelines: Key messages for clinical practice. Cardiac Failure Review, 9, e18. https://doi.org/10.15420/cfr.2023.08
Bloom, M. W., Herrmann, J., Ky, B., & Lenihan, D. J. (2025). Cardio-oncology and heart failure: A scientific statement from the Heart Failure Society of America. Journal of Cardiac Failure, 31(2), 145–170.
Dempsey, N., Rosenthal, A., Dabas, N., Kropotova, Y., Lippman, M., & Bishopric, N. H. (2021). Trastuzumab-induced cardiotoxicity: A review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Research and Treatment, 188(1), 21–36. https://doi.org/10.1007/s10549-021-06205-8
Mecinaj, A., Gulati, G., Heck, S. L., & Omland, T. (2024). Impact of the ESC cardio-oncology guidelines biomarker criteria in anthracycline-treated breast cancer patients. JACC: CardioOncology, 6(1), 85–97.
Mallidi, J., Lenneman, C., & Herrmann, J. (2024). Management of cancer therapy-related cardiac dysfunction in clinical practice. American Journal of Cardiology, 214, 88–99.
Witteles, R. M., & Telli, M. L. (2022). ESC cardio-oncology guidelines: A triumph—but are we ready for implementation? JACC: CardioOncology, 4(4), 639–642. https://doi.org/10.1016/j.jaccao.2022.10.002
The Role of Medical Verification
